EU/3/19/2237

Table of contents

About

On 9 January 2020, orphan designation EU/3/19/2237 was granted by the European Commission to Emerald Health Pharmaceuticals Espana S.L, Spain, for 2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone (also known as VCE-003.2) for the treatment of Huntington's disease.

Key facts

Active substance
2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone
Disease / condition
Treatment of Huntington's disease
Date of first decision
09/01/2020
Outcome
Positive
EU designation number
EU/3/19/2237

Sponsor's contact details

Emerald Health Pharmaceuticals Espana S.L.
Parque Científico Tecnológico de Córdoba (Rabanales 21)
C/ Astrónoma Cecilia Payne
Edificio Centauro
14014 Córdoba
Spain
Tel. + 34 6107 86932
e-mail: info@emeraldpharma.life

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating